Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
92 hedge funds and large institutions have $195M invested in Stemline Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 19 reducing their positions, and 14 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 19
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 90 → 92 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
31% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $2.31M
42% less capital invested
Capital invested by funds: $337M → $195M (-$143M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$12.8M |
| 2 |
ELI
Empire Life Investments
Toronto,
Ontario, Canada
|
+$3.56M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$3.22M |
| 4 |
Axa
Paris,
France
|
+$2.98M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
+$2.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$20.6M |
| 2 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$8.93M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.67M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.38M |
STML Hedge Fund Activity: Q4 2018 in Review
92 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2018, worth a combined $195M — down 42% from $337M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new STML positions and 14 closed out — a net gain of 3 holders — while 39 added to existing stakes and 19 trimmed.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $12.8M. The largest seller was Consonance Capital Management, cutting an estimated $20.6M.
- 92 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2018, up from 90 in Q3 2018.
- Funds reported $195M of Stemline Therapeutics, Inc. stock for Q4 2018, down 42% quarter-over-quarter.
- 17 funds opened new Stemline Therapeutics, Inc. positions in Q4 2018 and 14 closed out, a net change of +3 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q4 2018 was Manulife (Manufacturers Life Insurance), an estimated $12.8M added.
- The largest Stemline Therapeutics, Inc. seller in Q4 2018 was Consonance Capital Management, an estimated $20.6M sold.
Based on aggregated 13F filings for Q4 2018.